Figure 3From: Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 yearsMean scores on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) for weeks 26–234.Back to article page